Tessellate BIO Announces Appointment of Professor Sandra Strauss to Scientific Advisory Board

Amsterdam, the Netherlands and London, UK – 1 May 2024 - Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment of Professor Sandra Strauss, University College London, to its Scientific Advisory Board.

The SAB, which recently convened a successful meeting in San Diego ahead of the American Association for Cancer Research (AACR) Annual Meeting, brings together international experts to help guide the company’s scientific strategy and plays an important role in building Tessellate BIO’s academic networks so it can access cutting-edge research from international world-renowned laboratories to bring into its drug discovery programs.

Dr. Jurgen Moll, Tessellate BIO CSO, said: “Sandra is an acknowledged leader in the treatment of bone and soft tissue sarcomas in both adults and teenagers and it is an honor to welcome her to our SAB. She joins an international group whose expertise and counsel we hugely value as we seek to redefine Synthetic Lethality, taking it beyond its proven potential in Homology Recombination Deficiency, and into areas where it can impact more cancers and more patients.”

Prof. Sandra Strauss, University College London, said: “There is a clear need for new treatment approaches for many cancer indications and particularly for the treatment of sarcoma, where there has been very limited innovation, such that we commonly  still rely on toxic drugs originally developed many decades ago. Tessellate’s approach to precision oncology is an exciting development with a strong rationale in sarcoma and I look forward to working with the team and the rest of the SAB to help the company advance its programs and, ultimately, bring new potential treatments to patients.”

Sandra is Professor of Medical and Teenage Young Adult Cancer (TYA) and an honorary consultant medical oncologist at University College London Hospital NHS Trust. Her clinical role is based within the London Sarcoma Service, one of the largest sarcoma services in Europe. Here, she leads the clinical service, and specialises in the systemic treatment of bone and soft tissue sarcomas in both adults and teenagers. Her research appointment at UCL focuses on development of novel therapeutics in sarcomas across all ages.

She is the chief investigator and principal investigator for a number of international and national phase I, II and III studies in sarcoma and is leading a national cohort study in osteosarcoma, ICONIC. She chairs the NCRI Sarcoma Clinical Studies Group Bone Subgroup and the executive committee of the European EuroEwing consortium (EEC), a pan-European collaboration to improve outcome for patients with Ewing sarcoma.  She is also a member of the EORTC Soft Tissue and Bone Sarcoma Group and Innovative Therapies for Children with Cancer (ITCC) consortium and is the clinical lead for sarcoma and rare cancers for the Public Health England (PHE) National Cancer Registration and Analysis Service (NCRAS).